🏢 官网IRVCYTCodex · 实盘不做把握 1/10
北京时间·🕒 发布 04:05:00·⟳ 抓取 04:25:44 +20m44s·⚡ 决策 07-29 04:27:04 +1m20s·90.7 天前
Veracyte宣布参加两场投资者会议
公司仅公告将参加Canaccord和Morgan Stanley医疗投资者会议，并提供网络直播安排，没有披露订单、产品获批、财务指引或经营数据变化。
📄 原文VCYT↗ 原文
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnos…
不做 Veracyte（VCYT.US）
例行投资者会议参与公告，无明确方向、无经营或财务增量，不能形成同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 公司仅公告将参加Canaccord和Morgan Stanley医疗投资者会议，并提供网络直播安排，没有披露订单、产品获批、财务指引或经营数据变化。
主要风险
- 投资者会议本身可能带来后续管理层表述，但当前公告没有可交易的新增方向。
原文全文
展开原文 · 1,675 字
SOUTH SAN FRANCISCO, Calif.
,
July 28, 2026
(GLOBE NEWSWIRE) --
Veracyte, Inc.
(Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
Canaccord Genuity 46
th
Annual Growth Conference –
Boston, MA
Fireside chat on
Tuesday, Aug 11
th
at
10:30 a.m. Eastern Time
Morgan Stanley 24
th
Annual Global Healthcare Conference –
New York, NY
Fireside chat on
Tuesday, Sep 15
th
at
5:35 p.m. Eastern Time
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at
http://investor.veracyte.com/events-presentations
. Replays of the webcasts will be available for 90 days after each live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care.
Veracyte’s Diagnostics Platform
combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued
innovation and pipeline development
. The company’s portfolio includes the
Afirma® Genomic Sequencing Classifier test
,
Decipher® Bladder Genomic Classifier test
,
Decipher® Prostate Genomic Classifier test
,
Prosigna® Breast Risk of Recurrence test
, and the
TrueMRD™ Monitoring Test for MIBC
. For more information, visit Veracyte’s
website
or follow the company on
LinkedIn
or
X (Twitter)
.
Investors
Kelly Gura
investors@veracyte.com
Media
Molly Cornbleet
media@veracyte.com
+1-650-351-8780
,
July 28, 2026
(GLOBE NEWSWIRE) --
Veracyte, Inc.
(Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
Canaccord Genuity 46
th
Annual Growth Conference –
Boston, MA
Fireside chat on
Tuesday, Aug 11
th
at
10:30 a.m. Eastern Time
Morgan Stanley 24
th
Annual Global Healthcare Conference –
New York, NY
Fireside chat on
Tuesday, Sep 15
th
at
5:35 p.m. Eastern Time
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at
http://investor.veracyte.com/events-presentations
. Replays of the webcasts will be available for 90 days after each live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care.
Veracyte’s Diagnostics Platform
combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued
innovation and pipeline development
. The company’s portfolio includes the
Afirma® Genomic Sequencing Classifier test
,
Decipher® Bladder Genomic Classifier test
,
Decipher® Prostate Genomic Classifier test
,
Prosigna® Breast Risk of Recurrence test
, and the
TrueMRD™ Monitoring Test for MIBC
. For more information, visit Veracyte’s
website
or follow the company on
or
X (Twitter)
.
Investors
Kelly Gura
investors@veracyte.com
Media
Molly Cornbleet
media@veracyte.com
+1-650-351-8780
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。